The anti-histaminic cyproheptadine synergizes the antineoplastic activity of bortezomib in mantle cell lymphoma through its effects as a histone deacetylase inhibitor

Luca Paoluzzi, Luigi Scotto, Enrica Marchi, Venkatraman E. Seshan, Owen A. O'Connor

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Cyproheptadine, an inhibitor of the H1 histamine receptors, has recently shown activity in models of leukaemia and myeloma, presumably through inhibition of cyclin-D expression. Mantle cell lymphoma (MCL) is an aggressive subtype of non-Hodgkin lymphoma characterized by overexpression of cyclin-D1. We investigated the effect of cyproheptadine alone and in combination with the proteasome inhibitor bortezomib in models of MCL. The combination of these drugs was mathematically synergistic, producing significant reductions in the mitochondrial membrane potential leading to apoptosis. In a severe combined immunodeficient beige mouse model, cyproheptadine plus bortezomib demonstrated a statistically significant advantage compared to either agent alone.

Original languageEnglish (US)
Pages (from-to)656-659
Number of pages4
JournalBritish Journal of Haematology
Volume146
Issue number6
DOIs
StatePublished - Dec 1 2009
Externally publishedYes

Fingerprint

Cyproheptadine
Mantle-Cell Lymphoma
Histone Deacetylase Inhibitors
Antineoplastic Agents
Cyclin D
Histamine H1 Receptors
Proteasome Inhibitors
SCID Mice
Mitochondrial Membrane Potential
Cyclin D1
Drug Combinations
Non-Hodgkin's Lymphoma
Leukemia
Apoptosis
Bortezomib

Keywords

  • Bortezomib
  • Cyclin D1
  • Cyproheptadine
  • Hdac inhibitor
  • Mantle cell lymphoma

ASJC Scopus subject areas

  • Hematology

Cite this

The anti-histaminic cyproheptadine synergizes the antineoplastic activity of bortezomib in mantle cell lymphoma through its effects as a histone deacetylase inhibitor. / Paoluzzi, Luca; Scotto, Luigi; Marchi, Enrica; Seshan, Venkatraman E.; O'Connor, Owen A.

In: British Journal of Haematology, Vol. 146, No. 6, 01.12.2009, p. 656-659.

Research output: Contribution to journalArticle

@article{47cfdc76668e4a7293a8f75746a5878b,
title = "The anti-histaminic cyproheptadine synergizes the antineoplastic activity of bortezomib in mantle cell lymphoma through its effects as a histone deacetylase inhibitor",
abstract = "Cyproheptadine, an inhibitor of the H1 histamine receptors, has recently shown activity in models of leukaemia and myeloma, presumably through inhibition of cyclin-D expression. Mantle cell lymphoma (MCL) is an aggressive subtype of non-Hodgkin lymphoma characterized by overexpression of cyclin-D1. We investigated the effect of cyproheptadine alone and in combination with the proteasome inhibitor bortezomib in models of MCL. The combination of these drugs was mathematically synergistic, producing significant reductions in the mitochondrial membrane potential leading to apoptosis. In a severe combined immunodeficient beige mouse model, cyproheptadine plus bortezomib demonstrated a statistically significant advantage compared to either agent alone.",
keywords = "Bortezomib, Cyclin D1, Cyproheptadine, Hdac inhibitor, Mantle cell lymphoma",
author = "Luca Paoluzzi and Luigi Scotto and Enrica Marchi and Seshan, {Venkatraman E.} and O'Connor, {Owen A.}",
year = "2009",
month = "12",
day = "1",
doi = "10.1111/j.1365-2141.2009.07797.x",
language = "English (US)",
volume = "146",
pages = "656--659",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - The anti-histaminic cyproheptadine synergizes the antineoplastic activity of bortezomib in mantle cell lymphoma through its effects as a histone deacetylase inhibitor

AU - Paoluzzi, Luca

AU - Scotto, Luigi

AU - Marchi, Enrica

AU - Seshan, Venkatraman E.

AU - O'Connor, Owen A.

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Cyproheptadine, an inhibitor of the H1 histamine receptors, has recently shown activity in models of leukaemia and myeloma, presumably through inhibition of cyclin-D expression. Mantle cell lymphoma (MCL) is an aggressive subtype of non-Hodgkin lymphoma characterized by overexpression of cyclin-D1. We investigated the effect of cyproheptadine alone and in combination with the proteasome inhibitor bortezomib in models of MCL. The combination of these drugs was mathematically synergistic, producing significant reductions in the mitochondrial membrane potential leading to apoptosis. In a severe combined immunodeficient beige mouse model, cyproheptadine plus bortezomib demonstrated a statistically significant advantage compared to either agent alone.

AB - Cyproheptadine, an inhibitor of the H1 histamine receptors, has recently shown activity in models of leukaemia and myeloma, presumably through inhibition of cyclin-D expression. Mantle cell lymphoma (MCL) is an aggressive subtype of non-Hodgkin lymphoma characterized by overexpression of cyclin-D1. We investigated the effect of cyproheptadine alone and in combination with the proteasome inhibitor bortezomib in models of MCL. The combination of these drugs was mathematically synergistic, producing significant reductions in the mitochondrial membrane potential leading to apoptosis. In a severe combined immunodeficient beige mouse model, cyproheptadine plus bortezomib demonstrated a statistically significant advantage compared to either agent alone.

KW - Bortezomib

KW - Cyclin D1

KW - Cyproheptadine

KW - Hdac inhibitor

KW - Mantle cell lymphoma

UR - http://www.scopus.com/inward/record.url?scp=74549202247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74549202247&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2009.07797.x

DO - 10.1111/j.1365-2141.2009.07797.x

M3 - Article

C2 - 19604235

AN - SCOPUS:74549202247

VL - 146

SP - 656

EP - 659

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 6

ER -